top of page
News
Jun 18, 2025
La Jolla Labs featured in article about how a tailored ALS drug could help broaden rare disease therapies
"Beyond Ionis, the model is being pursued by various organizations, from the company La Jolla Labs to Boston Children's Hospital to the n-Lorem Foundation". La Jolla Labs is excited to continue our contribution to the N of 1 efforts, discovering therapeutics to rare diseases with unmet needs.
May 30, 2025
Co-Founder of La Jolla Labs', Jeff Milton, presents RNA Therapeutics: From Design to ASO Candidates, at the 2025 Mayo Clinic RNA Discoveries and Therapeutics Conference
La Jolla Labs' Co-Founder, Jeff Milton, will be presenting at the upcoming Mayo Clinic RNA Discoveries and Therapeutics Conference as a guest faculty speaker. His talk will be held Friday, May 30th from 2:30 - 3 pm and will cover the details of RNA therapeutics, from design to ASO candidates.
Feb 5, 2025
La Jolla Labs, Inc. Announces Leadership Transition as Company Evolves from Technology to Therapeutics
La Jolla Labs Co-founder Tamar Grossman, Ph.D., formerly Global Head of Gene Therapy, RNA, and Delivery at Johnson & Johnson, will assume the position of Chief Executive Officer. Dr. Grossman brings extensive experience in RNA therapeutics and drug delivery, positioning the company for its next phase of growth in developing transformative treatments.
Aug 24, 2023
Discussion Panelist at Invest in Cures San Diego 2023
La Jolla Labs CEO, Jeff Milton, joined the Innovation in Rare Disease Panel Discussion during LaunchBio's Invest In Cures Event to discuss how computational biology and machine learning may be used to address the unmet needs of rare disease patients.
Contact Us
bottom of page